Sofinnova Investments, Inc. — 13F Holdings & Portfolio

CIK 1631134 · latest 13F-HR filed 2026-05-15

Sofinnova Investments, Inc. manages $2.63B in 13F-reported U.S. long-equity assets across 75 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are NTRA (11.78%), IWM (5.66%), XBI (5.10%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 17 new positions, exited 16, added to 21, and trimmed 18.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$2.63B

Long-equity book

Holdings

75

Distinct positions

Period

2026-03-31

Filed 2026-05-15

Q/Q Activity

+17 / −16 / ↑21 / ↓18

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • Ultragenyx Pharmaceutical Inc$64.0M +3340.0%
  • Bristol-Myers Squibb Co$39.0M +47.8%
  • Axsome Therapeutics Inc.$33.7M +1505.1%
  • Insmed Inc$29.3M +107.4%
  • Alcon AG$28.8M +109.9%
Show all 21

Top Trims

  • Jazz Pharmaceuticals PLC-$50.1M -30.7%
  • Natera Inc-$45.1M -12.7%
  • Vera Therapeutics Inc-$29.1M -20.6%
  • BridgeBio Pharma Inc-$24.7M -44.9%
  • Praxis Precision Medicines Inc-$16.5M -44.6%
Show all 18

New Positions

  • AstraZeneca PLC$89.9M
  • Biogen Inc$42.1M
  • Genmab A/S$20.2M
  • Stryker Corporation$14.6M
  • Oric Pharmaceuticals Inc$8.6M
Show all 17

Exited Positions

  • ASTRAZENECA PLC$150.1M
  • VERTEX PHARMACEUTICALS INC$74.6M
  • ABBVIE INC$72.6M
  • INTUITIVE SURGICAL INC$71.9M
  • ELI LILLY & CO$66.3M
Show all 16
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Natera Inc NTRA 632307104 $310.0M 11.78% 1,550,280 SH
2 iShares TR Put IWM 464287655 $148.8M 5.66% 600,000 SH
3 SPDR Series Trust Put XBI 78464A870 $134.1M 5.10% 1,050,000 SH
4 Bristol-Myers Squibb Co BMY 110122108 $120.6M 4.58% 1,988,721 SH
5 Jazz Pharmaceuticals PLC JAZZ G50871105 $113.1M 4.30% 598,327 SH
6 Vera Therapeutics Inc VERA 92337R101 $112.4M 4.27% 2,793,987 SH
7 United Therapeutics Corp UTHR 91307C102 $94.9M 3.61% 160,070 SH
8 AstraZeneca PLC AZN G0593M107 $89.9M 3.42% 456,031 SH
9 Invesco QQQ TR Put QQQ 46090E103 $86.6M 3.29% 150,000 SH
10 Cogent Biosciences Inc COGT 19240Q201 $81.4M 3.09% 2,113,551 SH
11 iShares TR Put IBB 464287556 $80.2M 3.05% 475,000 SH
12 Ultragenyx Pharmaceutical Inc RARE 90400D108 $65.9M 2.50% 3,145,888 SH
13 Rapport Therapeutics Inc RAPP 75383L102 $59.6M 2.26% 1,904,408 SH
14 Insmed Inc INSM 457669307 $56.6M 2.15% 346,075 SH
15 Alcon AG ALC H01301128 $55.0M 2.09% 729,972 SH
16 Supernus Pharmaceuticals SUPN 868459108 $49.3M 1.87% 954,309 SH
17 United Therapeutics Corp Put UTHR 91307C102 $47.6M 1.81% 80,300 SH
18 BioMarin Pharmaceutical Inc BMRN 09061G101 $44.2M 1.68% 781,982 SH
19 Biogen Inc BIIB 09062X103 $42.1M 1.60% 229,521 SH
20 Celcuity Inc CELC 15102K100 $41.8M 1.59% 366,175 SH
21 BioAge Labs Inc BIOA 09077V100 $40.1M 1.52% 2,293,788 SH
22 Rhythm Pharmaceuticals Inc RYTM 76243J105 $39.1M 1.49% 450,096 SH
23 Arrivent BioPharma Inc AVBP 04272N102 $39.1M 1.49% 1,696,752 SH
24 IDEAYA Biosciences Inc IDYA 45166A102 $37.7M 1.43% 1,131,786 SH
25 Immunome Inc IMNM 45257U108 $37.2M 1.41% 1,701,904 SH
26 Nektar Therapeutics NKTR 640268306 $36.7M 1.39% 509,546 SH
27 Axsome Therapeutics Inc. AXSM 05464T104 $36.0M 1.37% 212,747 SH
28 Immatics N.V IMTX N44445109 $35.7M 1.36% 3,630,454 SH
29 Celcuity Inc Put CELC 15102K100 $34.2M 1.30% 300,000 SH
30 Axsome Therapeutics Inc. Put AXSM 05464T104 $33.8M 1.28% 200,000 SH
31 BridgeBio Pharma Inc BBIO 10806X102 $30.4M 1.15% 409,183 SH
32 Dyne Therapeutics Inc DYN 26818M108 $29.6M 1.13% 1,633,897 SH
33 Inhibrx Biosciences Inc INBX 45720N103 $27.3M 1.04% 406,029 SH
34 Dexcom Inc DXCM 252131107 $24.7M 0.94% 393,576 SH
35 Pharvaris N V PHVS N69605108 $23.1M 0.88% 818,328 SH
36 Pfizer Inc Call PFE 717081103 $22.5M 0.85% 800,000 SH
37 Praxis Precision Medicines Inc PRAX 74006W207 $20.5M 0.78% 63,680 SH
38 Genmab A/S GMAB 372303206 $20.2M 0.77% 752,261 SH
39 Arcus Biosciences Inc RCUS 03969F109 $19.9M 0.76% 923,086 SH
40 Liquidia Corporation Put LQDA 53635D202 $18.9M 0.72% 500,000 SH
41 Xenon Pharmaceuticals Inc XENE 98420N105 $17.7M 0.67% 305,216 SH
42 Stryker Corporation SYK 863667101 $14.6M 0.56% 44,480 SH
43 AnaptysBio Inc ANAB 032724106 $13.8M 0.52% 248,253 SH
44 Roivant Sciences Ltd ROIV G76279101 $13.2M 0.50% 477,995 SH
45 Edgewise Therapeutics Inc EWTX 28036F105 $12.2M 0.46% 386,498 SH
46 Compass Therapeutics Inc CMPX 20454B104 $10.9M 0.41% 2,056,161 SH
47 Exelixis Inc Put EXEL 30161Q104 $10.8M 0.41% 251,500 SH
48 Oric Pharmaceuticals Inc ORIC 68622P109 $8.6M 0.33% 679,578 SH
49 Tango Therapeutics Inc TNGX 87583X109 $8.3M 0.31% 395,081 SH
50 Tyra Biosciences Inc TYRA 90240B106 $7.8M 0.30% 204,015 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $2.63B 75 0001104659-26-062256
2025-12-31 2026-02-13 $2.32B 60 0001104659-26-015127
2025-09-30 2025-11-14 $1.83B 62 0001104659-25-111551